156 related articles for article (PubMed ID: 24360658)
1. Pharmacogenomics: New paradigms for targeted therapy based on individual response to drugs.
Ganapathi RN; Ganapathi MK
Urol Oncol; 2014 Jan; 32(1):1-4. PubMed ID: 24360658
[No Abstract] [Full Text] [Related]
2. [Antiblastic chemotherapy in urology].
Furnari S; Pavone-Macaluso S; Veroux G; Mattea E
Minerva Urol; 1971; 23(2):87-9. PubMed ID: 5105988
[No Abstract] [Full Text] [Related]
3. [Guideline for proper use of antineoplastic agents. Urologic cancer].
Akaza H; Miyanaga N
Gan To Kagaku Ryoho; 2002 Jun; 29(6):1055-64. PubMed ID: 12109446
[No Abstract] [Full Text] [Related]
4. Genitourinary cancer.
Hudes GR; Ozols RF; Schilder RJ
Cancer Chemother Biol Response Modif; 1991; 12():509-48. PubMed ID: 1718377
[No Abstract] [Full Text] [Related]
5. Selected clinical trials in prostrate, renal cell, and bladder cancer.
Clin Genitourin Cancer; 2007 Sep; 5(6):413. PubMed ID: 17990382
[No Abstract] [Full Text] [Related]
6. Pharmacogenomic considerations in the treatment of muscle-invasive bladder cancer.
Zuiverloon TC; Theodorescu D
Pharmacogenomics; 2017 Aug; 18(12):1167-1178. PubMed ID: 28745580
[TBL] [Abstract][Full Text] [Related]
7. Next-generation sequencing of urologic cancers: next is now.
Real FX; Boutros PC; Malats N
Eur Urol; 2014 Jul; 66(1):4-7. PubMed ID: 24731787
[TBL] [Abstract][Full Text] [Related]
8. Molecular targeting and pharmacogenomics in the management of advanced bladder cancer.
Raghavan D
Cancer; 2003 Apr; 97(8 Suppl):2083-9. PubMed ID: 12673700
[TBL] [Abstract][Full Text] [Related]
9. [Genitourinary cancers].
Mizuno R; Oya M
Nihon Rinsho; 2010 Aug; 68 Suppl 8():485-8. PubMed ID: 20979300
[No Abstract] [Full Text] [Related]
10. [The role of etoposide therapy in urogenital cancer].
Kawai K; Akaza H
Gan To Kagaku Ryoho; 1996 Dec; 23(14):1929-35. PubMed ID: 8978800
[TBL] [Abstract][Full Text] [Related]
11. [Molecular biology advances and perspectives in urology].
Feria Bernal G; Arroyo Kuribreña JC
Rev Invest Clin; 2003; 55(2):243-7. PubMed ID: 12827935
[No Abstract] [Full Text] [Related]
12. Genitourinary malignancies.
Smith MR; Kantoff P
Cancer Chemother Biol Response Modif; 1999; 18():394-417. PubMed ID: 10800495
[No Abstract] [Full Text] [Related]
13. Pharmacogenetics and pharmacogenomics as tools in cancer therapy.
Rodríguez-Vicente AE; Lumbreras E; Hernández JM; Martín M; Calles A; Otín CL; Algarra SM; Páez D; Taron M
Drug Metab Pers Ther; 2016 Mar; 31(1):25-34. PubMed ID: 26863347
[TBL] [Abstract][Full Text] [Related]
14. [Intra-arterial infusion of antineoplastic agents in the treatment of urogenital cancer].
Uyam T; Moriwaki S
Gan To Kagaku Ryoho; 1982 Mar; 9(3):415-20. PubMed ID: 7184407
[TBL] [Abstract][Full Text] [Related]
15. Theranostic and prognostic biomarkers: genomic applications in urological malignancies.
Netto GJ; Epstein JI
Pathology; 2010 Jun; 42(4):384-94. PubMed ID: 20438413
[TBL] [Abstract][Full Text] [Related]
16. [Role of multi-drug resistance in genito-urinary tumors].
Theyer G; Hamilton G
Prog Urol; 1993 Jun; 3(3):385-92; discussion 392-3. PubMed ID: 8103698
[No Abstract] [Full Text] [Related]
17. Pharmacogenetics and pharmacogenomics in oncology therapeutic antibody development.
Yan L; Beckman R
Biotechniques; 2005 Oct; 39(10 Suppl):S565-8. PubMed ID: 18957038
[TBL] [Abstract][Full Text] [Related]
18. The role of chemotherapy in the management of malignant urogenital neoplasms.
Schnipper LE
Urol Clin North Am; 1976 Jun; 3(2):423-32. PubMed ID: 960317
[No Abstract] [Full Text] [Related]
19. [Cytostatic therapy of metastasizing cancers: therapeutic indications and limitations (author's transl)].
Huber H; Denz H; Kratzer H
Wien Klin Wochenschr; 1977 Apr; 89(7):209-15. PubMed ID: 324137
[TBL] [Abstract][Full Text] [Related]
20. Genitourinary malignancy.
Haas N; Hudes GR
Cancer Chemother Biol Response Modif; 1997; 17():504-35. PubMed ID: 9551229
[No Abstract] [Full Text] [Related]
[Next] [New Search]
